The Prescribing Information is the primary source of information on the known and potential risks of emicizumab-kxwh for the prophylactic treatment of adult and pediatric patients with hemophilia A with or without factor VIII (FVIII) inhibitors. 

As of June 2020, more than 7,200 patients with hemophilia A with and without FVIII inhibitors have received emicizumab-kxwh globally through clinical trials, expanded access, compassionate use, and in the postmarketing setting.1

Global systems are in place to continuously monitor the safety of a drug.
Global safety data for emicizumab-kxwh and thrombotic microangiopathy, serious thrombotic events, and fatalities are currently available.1 Click below to learn more:

Postmarketing requirements and commitments2 are planned for emicizumab-kxwh. Click below to learn more from the FDA website:


HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.

Important Safety Information:

Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Report an Adverse Event
Genentech 24 hrs/day, 7 days/week (888) 835-2555 and/or the FDA (800) FDA‑1088

Medical Communications:
Submit a question online
Phone: (800) 821‑8590
Hours: Monday–Friday, 5:00 am–5:00 pm PT

Contact a Medical Science Liaison (MSL):
Request follow-up with an MSL

*Reflects reports of thrombotic microangiopathy (TMA), serious thrombotic events, and fatal events with sufficient details to verify the case and meet the reporting requirements for health authorities. Reports contained within this site include cases from emicizumab-kxwh clinical trials, expanded access, and compassionate use that may be assessed as related or unrelated to emicizumab-kxwh. This site also contains cases from postmarketing spontaneous adverse event reports. As of March 31, 2019 Genentech/Roche will not provide additional details related to serious adverse events reported in the postmarketing setting because the level of detail available and Genentech/Roche's ability to confirm individual details is variable. In addition, patient privacy is very important to Genentech/Roche, therefore we are careful not to disclose specific details about an adverse event that could jeopardize the privacy of either the patient or their family, or breach patient confidentiality. 



Data on file. Genentech, Inc. June 2020


U.S. Food and Drug Administration. Postmarketing Requirements and Commitments for HEMLIBRA® (emicizumab-kxwh). Accessed September 2019


US National Library of Medicine. Glossary of Common Site Terms. Accessed September 2019


US Food and Drugs Administration. Expanded Access (Compassionate Use).<br> Accessed September 2019


Jarow JP et al. Ther Innov Regul Sci. 2016;50(6):705-709


US Food and Drug Administration. Postmarketing Requirements and Commitments: Reports Accessed September 2019